Huons receives A grade in ESG evaluation

The company was recognized for excellence in environmental and social categories by KCGS

Huons receives A grade in ESG evaluation
Young-Ae Lee 1
Oct 31, 2024 (Gmt+09:00) 0ae@hankyung.com
Bio & Pharma

South Korea’s Huons Co. said on Tuesday that it received an A (excellent) grade in the 2024 ESG evaluation recently released by the Korea Institute of Corporate Governance and Sustainability (KCGS).

This year, Huons saw a three-level increase in the Environmental category, from "C" to "A," and a one-level rise in the Social category, from "B+" to "A."

The Governance category maintained its previous grade of "B+." Reflecting these improvements, Huons’ overall grade rose two levels from last year’s "B" to "A."

In the Environmental category, Huons established mid- to long-term goals and strategies for environmental management, conducted employee environmental education, launched an environmental campaign during Environment Week, and engaged in domestic environmental initiatives.

Huons upgraded aging facilities, replaced lights with LEDs, and tightened internal standards to reduce greenhouse gas emissions, waste, and water usage across six key areas.

In the Social category, as part of its responsible management, Huons engaged in community partnerships with welfare facilities in Seongnam and Jecheon, where its business sites are located, and participated in various community support activities.

Huons also contributed to community development and economic revitalization by supporting healthcare for vulnerable groups, offering educational opportunities, and running programs for multicultural family support.

Write to Young-Ae Lee at 0ae@hankyung.com

Huonslab eyes speedy anticancer drug delivery with new patent

Huonslab eyes speedy anticancer drug delivery with new patent

Huons Global's headquarters in Pangyo, Gyeonggi Province in Korea (Courtesy of Huons) South Korean biotech Huons Global Co. said on Tuesday that its research and development unit Huonslab has issued a domestic patent claiming a technology of human hyaluronidase PH20 production, which can help s

Huons’ overseas market expansion leads to record-high sales

Huons’ overseas market expansion leads to record-high sales

The bird eye view of Huons Biopharma's Jechon Plant 3  South Korea's Huons Group is continuing its record-breaking performance while expanding its influence in the global market.According to Huons Group on Tuesday, the consolidated financial statements of its holding company Huons Global f

Huons’ 2% lidocaine gets approval from FDA

Huons’ 2% lidocaine gets approval from FDA

South Korean pharmaceutical firm, Huons Co., announced on Monday that it has secured another significant regulatory milestone in the US with the Food and Drug Administration's (FDA) approval for the Abbreviated New Drug Application (ANDA) for its 2% lidocaine injection 5mL vial. Lidocaine is a

Huons sees tripling of lidocaine vial output in 3 years

Huons sees tripling of lidocaine vial output in 3 years

Huons CEO Yoon Sangbae worked at GlaxoSmithKline’s Korean operations before joining the generic anesthetics developer South Korea’s Huons Co., an anesthetics vial producer, aims to triple its lidocaine output from 2026, targeting the US market, where it fills the void left by multin

S.Korea's Huons gets approval to supply anesthetics to Canada

S.Korea's Huons gets approval to supply anesthetics to Canada

Huons Co., a South Korean pharmaceutical company, has announced plans to expand its presence in the North American market by offering two anesthetic drugs. The company confirmed on Tuesday that it has received approval from Health Canada, the government department responsible for national heal